Meaningful psoriasis improvement (PASI ≥50%, reduced plaque burden, decreased pruritus and impact on quality of life) is reported in 40–55% of treated cohorts over 12 weeks. Clearance rates (PASI 90–100%) are lower than with modern anti-TNF or anti-IL-17 biologics, ranging 15–25%. Responders tend to be moderate-severity (PASI 10–20 at baseline); severe or treatment-refractory phenotypes show variable outcomes. Stability of improvement depends on disease aetiology and concurrent stressor management.
Clinical trial data spans phase I safety and small phase II efficacy assessments involving 50–200 participants per study. Representative trials report psoriasis area and severity index (PASI) improvements of 50% or greater in 35–50% of infused cohorts over 12 weeks, with some achieving PASI 75 or 90 (near-complete clearance) in 20–30%. Erythema, scaling, and infiltration scores improve more consistently than pruritus. Remission duration in responders extends 3–8 months post-infusion; re-treatment may be required for sustained control. Compared to anti-TNF or anti-IL-17 biologics, MSC efficacy appears modest but comparable in blinded assessments.
Am I a candidate? → · Psoriasis: full overview → · Psoriasis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita